Resona Asset Management Co. Ltd. Has $75,000 Position in Charles River Laboratories International, Inc. $CRL

Resona Asset Management Co. Ltd. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 96.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 479 shares of the medical research company’s stock after selling 14,848 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Charles River Laboratories International were worth $75,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of CRL. D1 Capital Partners L.P. acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at $172,752,000. Assenagon Asset Management S.A. lifted its position in shares of Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock valued at $85,811,000 after acquiring an additional 538,792 shares during the period. Nomura Holdings Inc. acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at $56,820,000. SG Americas Securities LLC lifted its position in shares of Charles River Laboratories International by 16,153.2% during the 1st quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company’s stock valued at $40,219,000 after acquiring an additional 265,558 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Charles River Laboratories International by 24,226.8% during the 1st quarter. GAMMA Investing LLC now owns 210,427 shares of the medical research company’s stock valued at $31,673,000 after acquiring an additional 209,562 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on CRL. Wall Street Zen lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Sunday. JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. TD Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price target for the company in a research note on Wednesday, May 14th. Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and boosted their price target for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, Barclays boosted their price target on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an “equal weight” rating in a research note on Thursday, August 7th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus price target of $175.69.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $157.27 on Tuesday. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The firm has a market cap of $7.74 billion, a price-to-earnings ratio of -118.25, a PEG ratio of 5.00 and a beta of 1.48. The company has a fifty day moving average price of $157.06 and a 200-day moving average price of $148.69.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. During the same quarter in the prior year, the business posted $2.80 EPS. The business’s revenue was up .6% compared to the same quarter last year. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 400 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the transaction, the executive vice president owned 24,916 shares in the company, valued at approximately $3,738,396.64. This represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).